USANew treatments and approvals
Doxecitine and doxribtimine receive FDA approval as first treatment for TK2 deficiency
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA approved the combination of doxecitine and doxribtimine for children and adults with TK2 deficiency whose symptoms began at or before age 12. TK2 deficiency is a very rare mitochondrial disease involving muscle weakness and difficulty walking and breathing. The drug supplies building blocks to muscle cells to balance the function of the missing enzyme.
What does it mean for patients and families?
This disease previously had no approved treatment. This is the first option. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Thymidine kinase 2 (TK2) deficiency
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.